Pam Howland
About Pam Howland
Pam Howland: Vice President at Bolt Biotherapeutics
Pam Howland joined Bolt Biotherapeutics in 2022, taking on the role of Vice President, Portfolio and Program Management. With this position, she brings extensive experience, particularly in driving biotechnology programs through various phases including Investigational New Drug (IND), clinical development, regulatory approval, and commercial launch.
Pam Howland's Career in Biotechnology
Pam Howland boasts over 20 years of experience in the biotechnology sector. Prior to her current role at Bolt Biotherapeutics, she contributed significantly at Lyell Immunopharma, where she was responsible for advancing the first two lead cell therapy programs through IND and into clinical trials. Her career also includes a tenure at Pellepharm Inc., part of BridgeBio, as Vice President, Project and Alliance Management, where she supported research collaborations and the eventual commercialization of the program.
Pam Howland's Contributions at Sunesis Pharmaceuticals
Pam Howland spent a decade at Sunesis Pharmaceuticals, which is now Viracta Therapeutics, managing the vosaroxin program from Phase 2 development through to the planning and execution of the Phase 3 clinical program. Her leadership was instrumental in the regulatory submission and defense of the program.
Pam Howland's Educational Background
Pam Howland holds two Master of Science degrees, one from Stanford University and another from the University of Santa Clara. She earned her Bachelor of Science degree from Brown University. Her academic qualifications have solidified her foundation in the biotechnological sciences, supporting her extensive career achievements.
Pam Howland: Roles at Jazz Pharmaceuticals and Cepheid
In addition to her major roles, Pam Howland has also held program management positions at Jazz Pharmaceuticals and Cepheid. These roles further underpin her extensive experience in managing complex biotechnology and pharmaceutical projects.